FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229706095> ?p ?o ?g. }

• W4229706095 endingPage "1774" @default.
• W4229706095 startingPage "1771" @default.
• W4229706095 abstract "<h3>Objective.</h3> —To determine if lowering elevated low-density lipoprotein cholesterol (LDL-C) levels offsets the adverse effect of raised lipoprotein(a) (Lp[a]) levels on coronary artery disease (CAD) in men. <h3>Design.</h3> —Randomized, double-blind, placebo-controlled trial of lipid lowering for CAD. <h3>Setting.</h3> —Post hoc analysis of the Familial Atherosclerosis Treatment Study. <h3>Participants.</h3> —A total of 146 men aged 62 years or younger with CAD and apolipoprotein B levels of at least 125 mg/dL. <h3>Intervention.</h3> —Patients received a Step II Diet and lovastatin (40 mg daily) plus colestipol (30 g daily), niacin (4 g daily) plus colestipol, or placebo (plus colestipol if LDL-C >90th percentile) for 2.5 years. They were grouped by their LDL-C responses: minimal if LDL-C decreased by 10% or less from baseline (mean [SD] change, +6% [13%]) and substantial if LDL-C decreased more than 10% (mean [SD] change, —40% [16%]). <h3>Main Outcome Measure.</h3> —Impact of lowering elevated LDL-C on the cardiac event rate (death, myocardial infarction, and revascularization for refractory ischemia) and CAD change associated with elevated Lp(a). <h3>Results.</h3> —In multivariate analyses, the best correlate of baseline CAD severity was Lp(a) (<i>r</i>=0.30;<i>P</i><.001). For 36 patients with minimal LDL-C reduction, CAD progression correlated only with in-treatment Lp(a) levels (<i>r</i>=0.45;<i>P</i><.01), but for 84 patients with substantial LDL-C reduction, disease regressed and its change correlated with in-treatment LDL-C (<i>r</i>=0.24;<i>P</i><.05) but not with Lp(a) (<i>r</i>=—0.05). Lipoprotein(a) levels were not significantly altered in either group. For 40 patients with Lp(a) at the 90th percentile or higher, events were frequent (39%) if reduction of LDL-C was minimal, but were few (9%) if reduction was substantial (relative risk, 0.23; 95% confidence interval, 0.06 to 0.99). <h3>Conclusions.</h3> —In men with CAD and elevated LDL-C, Lp(a) levels were dominant correlates of baseline disease severity, its progression, and event rate over 2.5 years. However, with substantial LDL-C reductions, persistent elevations of Lp(a) were no longer atherogenic or clinically threatening. This provides a possible direction for treatment in such patients with elevated Lp(a) and LDL-C. (<i>JAMA</i>. 1995;274:1771-1774)" @default.
• W4229706095 created "2022-05-11" @default.
• W4229706095 creator A5051410574 @default.
• W4229706095 date "1995-12-13" @default.
• W4229706095 modified "2023-10-16" @default.
• W4229706095 title "Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)" @default.
• W4229706095 doi "https://doi.org/10.1001/jama.274.22.1771" @default.
• W4229706095 hasPublicationYear "1995" @default.
• W4229706095 type Work @default.
• W4229706095 citedByCount "30" @default.
• W4229706095 countsByYear W42297060952013 @default.
• W4229706095 countsByYear W42297060952017 @default.
• W4229706095 crossrefType "journal-article" @default.
• W4229706095 hasAuthorship W4229706095A5051410574 @default.
• W4229706095 hasConcept C126322002 @default.
• W4229706095 hasConcept C134018914 @default.
• W4229706095 hasConcept C142724271 @default.
• W4229706095 hasConcept C164705383 @default.
• W4229706095 hasConcept C204787440 @default.
• W4229706095 hasConcept C27081682 @default.
• W4229706095 hasConcept C2776104379 @default.
• W4229706095 hasConcept C2778163477 @default.
• W4229706095 hasConcept C2778213512 @default.
• W4229706095 hasConcept C2780072125 @default.
• W4229706095 hasConcept C2780092750 @default.
• W4229706095 hasConcept C500558357 @default.
• W4229706095 hasConcept C62746215 @default.
• W4229706095 hasConcept C71924100 @default.
• W4229706095 hasConcept C90924648 @default.
• W4229706095 hasConceptScore W4229706095C126322002 @default.
• W4229706095 hasConceptScore W4229706095C134018914 @default.
• W4229706095 hasConceptScore W4229706095C142724271 @default.
• W4229706095 hasConceptScore W4229706095C164705383 @default.
• W4229706095 hasConceptScore W4229706095C204787440 @default.
• W4229706095 hasConceptScore W4229706095C27081682 @default.
• W4229706095 hasConceptScore W4229706095C2776104379 @default.
• W4229706095 hasConceptScore W4229706095C2778163477 @default.
• W4229706095 hasConceptScore W4229706095C2778213512 @default.
• W4229706095 hasConceptScore W4229706095C2780072125 @default.
• W4229706095 hasConceptScore W4229706095C2780092750 @default.
• W4229706095 hasConceptScore W4229706095C500558357 @default.
• W4229706095 hasConceptScore W4229706095C62746215 @default.
• W4229706095 hasConceptScore W4229706095C71924100 @default.
• W4229706095 hasConceptScore W4229706095C90924648 @default.
• W4229706095 hasIssue "22" @default.
• W4229706095 hasLocation W42297060951 @default.
• W4229706095 hasOpenAccess W4229706095 @default.
• W4229706095 hasPrimaryLocation W42297060951 @default.
• W4229706095 hasRelatedWork W1845885551 @default.
• W4229706095 hasRelatedWork W1999705294 @default.
• W4229706095 hasRelatedWork W2025648868 @default.
• W4229706095 hasRelatedWork W2032202705 @default.
• W4229706095 hasRelatedWork W2032584647 @default.
• W4229706095 hasRelatedWork W2147702047 @default.
• W4229706095 hasRelatedWork W2317167974 @default.
• W4229706095 hasRelatedWork W2320029659 @default.
• W4229706095 hasRelatedWork W2414285587 @default.
• W4229706095 hasRelatedWork W2618630717 @default.
• W4229706095 hasVolume "274" @default.
• W4229706095 isParatext "false" @default.
• W4229706095 isRetracted "false" @default.
• W4229706095 workType "article" @default.